Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy

Moira Cruickshank; Charlotte Kennedy; Lorna Aucott; Corinne Booth; Mari Imamura; Thenmalar Vadiveloo; Paul Manson; Gavin Preston; Graham Scotland; Miriam Brazzelli

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy

Moira Cruickshank, Charlotte Kennedy, Lorna Aucott, Corinne Booth, Mari Imamura, Thenmalar Vadiveloo, Paul Manson, Gavin Preston, Graham Scotland, Miriam Brazzelli^* (Corresponding Author)

^*Corresponding author for this work

Research output: Book/Report › Commissioned Report

Abstract

Evidence Review Group report in support of NICE STA Programme.

Original language	English
Place of Publication	London
Publisher	National Institute for Health and Care Excellence (NICE)
Publication status	Published - 28 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://njl-admin.nihr.ac.uk/document/download/2037726Licence: Unspecified

Cite this

Cruickshank, M., Kennedy, C., Aucott, L., Booth, C., Imamura, M., Vadiveloo, T., Manson, P., Preston, G., Scotland, G., & Brazzelli, M. (2021). Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy. National Institute for Health and Care Excellence (NICE). https://njl-admin.nihr.ac.uk/document/download/2037726

Cruickshank, M , Kennedy, C , Aucott, L, Booth, C, Imamura, M , Vadiveloo, T, Manson, P, Preston, G, Scotland, G & Brazzelli, M 2021, Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy. National Institute for Health and Care Excellence (NICE), London. <https://njl-admin.nihr.ac.uk/document/download/2037726>

@book{e661f4a8f3de4fa98809cea3476ef78f,

title = "Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy",

abstract = "Evidence Review Group report in support of NICE STA Programme.",

author = "Moira Cruickshank and Charlotte Kennedy and Lorna Aucott and Corinne Booth and Mari Imamura and Thenmalar Vadiveloo and Paul Manson and Gavin Preston and Graham Scotland and Miriam Brazzelli",

year = "2021",

month = may,

day = "28",

language = "English",

publisher = "National Institute for Health and Care Excellence (NICE)",

}

TY - BOOK

T1 - Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy

AU - Cruickshank, Moira

AU - Kennedy, Charlotte

AU - Aucott, Lorna

AU - Booth, Corinne

AU - Imamura, Mari

AU - Vadiveloo, Thenmalar

AU - Manson, Paul

AU - Preston, Gavin

AU - Scotland, Graham

AU - Brazzelli, Miriam

PY - 2021/5/28

Y1 - 2021/5/28

N2 - Evidence Review Group report in support of NICE STA Programme.

AB - Evidence Review Group report in support of NICE STA Programme.

UR - https://www.nice.org.uk/guidance/TA765

M3 - Commissioned Report

BT - Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy

PB - National Institute for Health and Care Excellence (NICE)

CY - London

ER -

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this